Anti-leukemic properties of IL-12, IL-23 and IL-27: Differences and similarities in the control of pediatric B acute lymphoblastic leukemia

Critical Reviews in Oncology/Hematology

Volumn 83, Issue 3, 2012, Pages 310-318

  Cocco, Claudia ^a   Pistoia, Vito ^a   Airoldi, Irma ^a  

^a G GASLINI INSTITUTE   (Italy)

Author keywords

B ALL; Cytokine receptors; Cytokines

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; INTERLEUKIN 12; INTERLEUKIN 23; INTERLEUKIN 27; MICRORNA 15A; PLASMID DNA; RITUXIMAB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; B CELL LEUKEMIA; BREAST CANCER; CANCER GENE THERAPY; CANCER STAGING; CHILDHOOD LEUKEMIA; COLON CANCER; HUMAN; LEUKEMIA; LEUKEMIA CELL; LEUKEMIA RELAPSE; MELANOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SOLID TUMOR; TH17 CELL; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; INTERLEUKINS; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 84864914763     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.11.006     Document Type: Review

References (85)

1. Hunter C.A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005, 5:521-531.
2. Kobayashi M., Fitz L., Ryan M., et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989, 170:827-845.
3. Presky D.H., Yang H., Minetti L.J., et al. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci USA 1996, 93:14002-14007.
4. Oppmann B., Lesley R., Blom B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
5. Parham C., Chirica M., Timans J., et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002, 168:5699-5708.
6. Pflanz S., Timans J.C., Cheung J., et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002, 16:779-790.
7. Pflanz S., Hibbert L., Mattson J., et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 2004, 172:2225-2231.
8. Chen Q., Ghilardi N., Wang H., et al. Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature 2000, 407:916-920.
9. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3:133-146.
10. Aggarwal S., Ghilardi N., Xie M.H., de Sauvage F.J., Gurney A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003, 278:1910-1914.
11. Yoshimoto T., Yoshimoto T., Yasuda K., Mizuguchi J., Nakanishi K. IL-27 suppresses Th2 cell development and Th2 cytokines production from polarized Th2 cells: a novel therapeutic way for Th2-mediated allergic inflammation. J Immunol 2007, 179:4415-4423.
12. Stumhofer J.S., Silver J.S., Laurence A., et al. Interleukins 27 and 6 induce STAT3-mediated T cell production of interleukin 10. Nat Immunol 2007, 8:1363-1371.
13. Fitzgerald D.C., Zhang G.X., El-Behi M., et al. Suppression of autoimmune inflammation of the central nervous system by interleukin 10 secreted by interleukin 27-stimulated T cells. Nat Immunol 2007, 8:1372-1379.
14. Lexberg M.H., Taubner A., Albrecht I., et al. IFN-gamma and IL-12 synergize to convert in vivo generated Th17 into Th1/Th17 cells. Eur J Immunol 2010, 40:3017-3027.
15. Lee Y.K., Turner H., Maynard C.L., et al. Late developmental plasticity in the T helper 17 lineage. Immunity 2009, 30:92-107.
16. Airoldi I., Gri G., Marshall J.D., et al. Expression and function of IL-12 and IL-18 receptors on human tonsillar B cells. J Immunol 2000, 165:6880-6888.
17. Boumendjel A., Tawk L., Malefijt Rde W., Boulay V., Yssel H., Pene J. IL-27 induces the production of IgG1 by human B cells. Eur Cytokine Netw 2006, 17:281-289.
18. Cocco C., Morandi F., Airoldi I. Interleukin-27 and interleukin-23 modulate human plasmacell functions. J Leukoc Biol 2011, 89:729-734.
19. Langowski J.L., Zhang X., Wu L., et al. IL-23 promotes tumour incidence and growth. Nature 2006, 442:461-465.
20. Oniki S., Nagai H., Horikawa T., et al. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 2006, 66:6395-6404.
21. Xu M., Mizoguchi I., Morishima N., Chiba Y., Mizuguchi J., Yoshimoto T. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol 2010, pii:832454.
22. Lo C.H., Lee S.C., Wu P.Y., et al. Antitumor and antimetastatic activity of IL-23. J Immunol 2003, 171:600-607.
23. Wang Y.Q., Ugai S., Shimozato O., et al. Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Int J Cancer 2003, 105:820-824.
24. Langowski J.L., Kastelein R.A., Oft M. Swords into plowshares: IL-23 repurposes tumor immune surveillance. Trends Immunol 2007, 28:207-212.
25. Hisada M., Kamiya S., Fujita K., et al. Potent antitumor activity of interleukin-27. Cancer Res 2004, 64:1152-1156.
26. Shimizu M., Shimamura M., Owaki T., et al. Antiangiogenic and antitumor activities of IL-27. J Immunol 2006, 176:7317-7324.
27. Brunda M.J., Luistro L., Warrier R.R., et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993, 178:1223-1230.
28. Voest E.E., Kenyon B.M., O'Reilly M.S., Truitt G., D'Amato R.J., Folkman J. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995, 87:581-586.
29. Cocco C., Canale S., Frasson C., et al. Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells. Blood 2010, 116:3887-3898.
30. Cocco C., Giuliani N., Di Carlo E., et al. IL-27 acts as multifunctional anti-tumor agent in multiple myeloma. Clin Cancer Res 2010, 16:4188-4197.
31. Pistoia V., Cocco C., Airoldi I. Interleukin-12 receptor beta2: from cytokine receptor to gatekeeper gene in human B-cell malignancies. J Clin Oncol 2009, 27:4809-4816.
32. Airoldi I., Di Carlo E., Cocco C., et al. IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions. PLoS One 2009, 4:e6119.
33. Canale S., Cocco C., Frasson C., et al. Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model. Leukemia 2011, 10.1038/leu.2011.158.
34. Airoldi I., Di Carlo E., Cocco C., et al. Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci USA 2007, 104:3996-4001.
35. Yoshimoto T., Morishima N., Mizoguchi I., et al. Antiproliferative activity of IL-27 on melanoma. J Immunol 2008, 180:6527-6535.
36. Ferretti E., Di Carlo E., Cocco C., et al. Direct inhibition of human acute myeloid leukemia cell growth by IL-12. Immunol Lett 2010, 133:99-105.
37. Ferretti E., Montagna D., Di Carlo E., et al. Absence of IL-12Rbeta2 in CD33(+)CD38(+) pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RgammaC-deficient mice. Leukemia 2011, 10.1038/leu.2011.213.
38. Airoldi I., Di Carlo E., Banelli B., et al. The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies. J Clin Invest 2004, 113:1651-1659.
39. Airoldi I., Cocco C., Giuliani N., et al. Constitutive expression of IL-12R beta 2 on human multiple myeloma cells delineates a novel therapeutic target. Blood 2008, 112:750-759.
40. Airoldi I., Cocco C., Di Carlo E., et al. Methylation of the IL-12Rbeta2 gene as novel tumor escape mechanism for pediatric B-acute lymphoblastic leukemia cells. Cancer Res 2006, 66:3978-3980.
41. Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer 2006, 6:193-203.
42. Carroll W.L., Bhojwani D., Min D.J., et al. Pediatric acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2003, 10:2-31.
43. Pieters R., Carroll W.L. Biology and treatment of acute lymphoblastic leukemia. Pediatr Clin North Am 2008, 55:1-20.
44. Ravandi F. Role of cytokines in the treatment of acute leukemias: a review. Leukemia 2006, 20:563-571.
45. Wu S., Gessner R., von Stackelberg A., Kirchner R., Henze G., Seeger K. Cytokine/cytokine receptor gene expression in childhood acute lymphoblastic leukemia: correlation of expression and clinical outcome at first disease recurrence. Cancer 2005, 103:1054-1063.
46. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
47. Bonci D., Coppola V., Musumeci M., et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med 2008, 14:1271-1277.
48. Cimmino A., Calin G.A., Fabbri M., et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005, 102:13944-13949.
49. Cory S., Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002, 2:647-656.
50. Stacey D.W. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol 2003, 15:158-163.
51. Motokura T., Arnold A. Cyclin D and oncogenesis. Curr Opin Genet Dev 1993, 3:5-10.
52. Cory S., Huang D.C., Adams J.M. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003, 22:8590-8607.
53. Klein U., Lia M., Crespo M., et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010, 17:28-40.
54. Gao S.M., Yang J., Chen C., Zhang S., Xing C.Y., Li H., et al. miR-15a/16-1 enhances retinoic acid-mediated differentiation of leukemic cells and is up-regulated by retinoic acid. Leuk Lymphoma 2011, 55:2365-2371.
55. Costinean S., Sandhu S.K., Pedersen I.M., et al. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. Blood 2009, 114:1374-1382.
56. Eis P.S., Tam W., Sun L., et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 2005, 102:3627-3632.
57. O'Connell R.M., Rao D.S., Chaudhuri A.A., et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med 2008, 205:585-594.
58. Yanaihara N., Caplen N., Bowman E., et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006, 9:189-198.
59. Gironella M., Seux M., Xie M.J., et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA 2007, 104:16170-16175.
60. Nikiforova M.N., Tseng G.C., Steward D., Diorio D., Nikiforov Y.E. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 2008, 93:1600-1608.
61. Jiang S., Zhang H.W., Lu M.H., et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 2010, 70:3119-3127.
62. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269.
63. Vigorito E., Perks K.L., Abreu-Goodger C., et al. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity 2007, 27:847-859.
64. Costinean S., Zanesi N., Pekarsky Y., et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 2006, 103:7024-7029.
65. Moehler T.M., Ho A.D., Goldschmidt H., Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 2003, 45:227-244.
66. Ribatti D. Bone marrow vascular niche and the control of tumor growth in hematological malignancies. Leukemia 2010, 24:1247-1248.
67. Cox C.V., Blair A. A primitive cell origin for B-cell precursor ALL. Stem Cell Rev. 2005, 1:189-196.
68. Scandura J.M., Roboz G.J., Moh M., et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood 2011, 118:1472-1480.
69. Leonard J.P., Sherman M.L., Fisher G.L., et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997, 90:2541-2548.
70. Motzer R.J., Rakhit A., Thompson J.A., et al. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res 2001, 21:257-263.
71. Portielje J.E., Kruit W.H., Schuler M., et al. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res 1999, 5:3983-3989.
72. Robertson M.J., Cameron C., Atkins M.B., et al. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res 1999, 5:9-16.
73. Heinzerling L., Burg G., Dummer R., et al. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 2005, 16:35-48.
74. Kang W.K., Park C., Yoon H.L., et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther 2001, 12:671-684.
75. Sun Y., Jurgovsky K., Moller P., et al. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther 1998, 5:481-490.
76. Younes A., Pro B., Robertson M.J., et al. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res 2004, 10:5432-5438.
77. Zhu S., Lee D.A., Li S.I. IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors. J Immunol 2010, 184:2348-2354.
78. Zou W., Restifo N.P. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010, 10:248-256.
79. Alexandrakis M.G., Pappa C.A., Miyakis S., et al. Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma. Eur J Intern Med 2006, 17:412-416.
80. Tripodo C., Gri G., Piccaluga P.P., et al. Mast cells and Th17 cells contribute to the lymphoma-associated pro-inflammatory microenvironment of angioimmunoblastic T-cell lymphoma. Am J Pathol 2010, 177:792-802.
81. Wilke C.M., Kryczek I., Wei S., et al. Th17 cells in cancer: help or hindrance. Carcinogenesis 2011, 32:643-649.
82. Kryczek I., Banerjee M., Cheng P., et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009, 114:1141-1149.
83. Lee Y.K., Mukasa R., Hatton R.D., Weaver C.T. Developmental plasticity of Th17 and Treg cells. Curr Opin Immunol 2009, 21:274-280.
84. Seita J., Asakawa M., Ooehara J., et al. Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood 2008, 111:1903-1912.
85. Bellone G., Trinchieri G. Dual stimulatory and inhibitory effect of NK cell stimulatory factor/IL-12 on human hematopoiesis. J Immunol 1994, 153:930-937.